Repligen (NASDAQ:RGEN) Releases FY24 Earnings Guidance

Repligen (NASDAQ:RGEN) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $1.50-1.58 for the period, compared to the consensus estimate of $1.44. The company issued revenue guidance of $630-639 million, compared to the consensus revenue estimate of $629.61 million. Repligen also updated its FY 2024 guidance to 1.500-1.580 EPS.

Repligen Stock Performance

Shares of RGEN traded down $8.88 during mid-day trading on Friday, reaching $133.55. The company’s stock had a trading volume of 136,573 shares, compared to its average volume of 657,876. Repligen has a 1-year low of $113.50 and a 1-year high of $211.13. The stock has a market cap of $7.48 billion, a P/E ratio of -361.50, a PEG ratio of 4.36 and a beta of 0.96. The business has a 50-day simple moving average of $141.59 and a two-hundred day simple moving average of $144.78. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.92% and a negative net margin of 3.36%. The company had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. During the same period last year, the firm posted $0.23 earnings per share. The business’s revenue was up 9.7% on a year-over-year basis. As a group, equities research analysts anticipate that Repligen will post 1.44 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

RGEN has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. raised their price objective on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 31st. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a report on Wednesday. Wells Fargo & Company initiated coverage on Repligen in a report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price target for the company. UBS Group dropped their price target on Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Finally, Wolfe Research assumed coverage on Repligen in a report on Thursday. They set a “peer perform” rating for the company. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $190.25.

Insider Buying and Selling

In related news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now owns 139,840 shares in the company, valued at $20,328,540.80. The trade was a 13.70 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.20% of the stock is currently owned by corporate insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.